July 2, 2025 11:40 AM EDTUpdated 01:04 PM
Pharma
FDA+

Af­ter de­lay, Re­gen­eron wins US ap­proval of bis­pe­cif­ic in mul­ti­ple myelo­ma

Lei Lei Wu

News Reporter

At long last, Re­gen­eron is bring­ing a bis­pe­cif­ic an­ti­body drug for mul­ti­ple myelo­ma to the US mar­ket.

The com­pa­ny said Wednes­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: FDA pub­lish­es repos­i­to­ry of 200+ drug re­jec­tion let­ters, promis­ing more in the fu­ture

Biotech’s Q2 num­bers paint a pic­ture of the good, the bad and the ug­ly

Ab­b­Vie inks $700M deal with IGI for mul­ti­ple myelo­ma trispe­cif­ic an­ti­body

Who pays the most in bio­phar­ma? We an­a­lyzed me­di­an pay at 177 com­pa­nies

Var­da rais­es $187M to ad­vance drug man­u­fac­tur­ing in space

sponsored

Un­cov­er­ing the Po­ten­tial of Tar­get­ing the CD38 Path­way for Im­mune-Me­di­at­ed Dis­eases

A service from the Financial Times